
Closely held PharmaJet has announced that their WHO-prequalified Tropis ID Needle-free Injection System has been used to deliver more than 25 million needle-free injections in support of polio eradication.
According to PharmaJet, polio immunization campaigns in Pakistan, Somalia, and Nigeria have demonstrated that Tropis is an effective and preferred solution that can help increase campaign coverage by over 18%. A published study in Vaccines also highlighted that, when compared to the standard of care (full dose with needles), administration with Tropis increased coverage of the second dose of IPV (IPV2) (11.2% higher); decreased total immunization costs up to 47%; and achieved 97% healthcare worker preference. Recently, Tropis has also been adopted for polio vaccination campaigns in Afghanistan and PharmaJet is expanding into additional countries.
In a statement, Paul LaBarre, senior vice president global business development, PharmaJet, commented, “PharmaJet has supported needle-free polio vaccination campaigns in Pakistan since 2018 and we are pleased that, with recent expansion into Afghanistan and Nigeria campaigns, we have reached this important 25 million injections milestone. While our patented needle-free technology has been shown to improve coverage, with high acceptability and cost savings, we are also excited about the new applications our pharmaceutical partners are discovering including a registrational Phase 3 study for Scancell’s oncology immunotherapy delivered with our Stratis Intramuscular System.”






